UNITED
STATES
SECURITIES
AND EXCHANGE COMMISSION
WASHINGTON,
D.C. 20549
__________
FORM
8-K
CURRENT
REPORT
Pursuant
to Section 13 or 15(d) of the
Securities
Exchange Act of 1934
Date
of Report (Date of earliest event reported): May 8, 2009
AngioDynamics,
Inc.
(Exact
Name of Registrant as Specified in Charter)
|
Delaware
|
000-50761
|
11-3146460
|
|
(State
or Other Jurisdiction
of Incorporation)
|
(Commission
File
Number)
|
(IRS
Employer
Identification
No.)
|
|
603
Queensbury Avenue, Queensbury, New York
|
12804
|
||
|
(Address
of Principal Executive Offices)
|
(Zip
Code)
|
(518)
798-1215
(Registrant’s
telephone number, including area code)
Check the appropriate box
below if the Form 8-K filing is intended to simultaneously satisfy the filing
obligation of the registrant under any of the following provisions:
|
o
|
Written
communications pursuant to Rule 425 under the Securities Act (17 CFR
230.425)
|
|
|
o
|
Soliciting
material pursuant to Rule 14a-12 under the Exchange Act (17 CFR
240.14a-12)
|
|
|
o
|
Pre-commencement
communications pursuant to Rule 14d-2(b) under the Exchange Act (17
CFR 240.14d-2 (b))
|
|
|
o
|
Pre-commencement
communications pursuant to Rule 13e-4(c) under the Exchange Act (17
CFR 240.13e-4
(c))
|
Item
5.02 – Departure of Directors or Certain Officers; Election of Directors;
Appointment of Certain Officers; Compensatory Arrangement of Certain
Officers.
Effective
May 8, 2009, Eamonn P. Hobbs resigned as a member of the board of directors of
AngioDynamics, Inc. (“AngioDynamics”). Mr. Hobbs’ resignation was
not the result of any disagreement with AngioDynamics.
On
May 11, 2009, AngioDynamics’ Board of
Directors appointed Jan Keltjens, President and CEO, to the board to fill the
vacancy created by Mr. Hobbs’
resignation. Mr. Keltjens was appointed to the class of directors
whose term expires at AngioDynamics’ 2009 annual
meeting. The material terms of Mr. Keltjens’ employment arrangement
with AngioDynamics were disclosed in AngioDynamics’ Current Report on
Form 8-K, filed with the Securities Exchange Commission on January 23, 2009 (the
“January 23, 2009 8-K”).
In
addition, on May 11, 2009, AngioDynamics’ board of
directors agreed to pay Mr. Hobbs an advance of $200,000 against the amount owed
to Mr. Hobbs pursuant to Section 7 of the employment agreement, dated January
20, 2009, between AngioDynamics and Mr. Hobbs. The material terms of
the employment agreement were disclosed in, and a copy of the employment
agreement was filed as Exhibit 10.5 to, the January 23, 2009 8-K.
Item
7.01 – Regulation FD Disclosure.
On
May 11, 2009, AngioDynamics issued a press release announcing the appointment of
Mr. Keltjens to AngioDynamics’ board of
directors. A copy of the Press release is furnished with this Form
8-K and attached hereto as Exhibit 99.1.
The
information set forth in Item 7.01 of this Form 8-K (including Exhibit 99.1)
shall not be deemed “filed” for purposes of Section 18 of the Securities
Exchange Act of 1934, as amended (the Exchange Act), or incorporated by
reference in any filing under the Securities Act of 1933, as amended, or the
Exchange Act, except as shall be expressly set forth by specific reference in
such a filing.
Item
9.01 – Financial Statements and Exhibits.
(d) Exhibits.
|
Exhibit No.
|
Description
|
|
|
99.1
|
Press
Release dated May 11, 2009.
|
SIGNATURE
Pursuant
to the requirements of the Securities Exchange Act of 1934, the registrant has
duly caused this report to be signed on its behalf by the undersigned hereunto
duly authorized.
|
ANGIODYNAMICS,
INC.
|
|||
|
(Registrant)
|
|||
|
Date:
May 11, 2009
|
By:
|
/s/
D. Joseph Gersuk
|
|
|
D.
Joseph Gersuk
|
|||
|
Chief
Financial Officer
|
|||
EXHIBIT
INDEX
|
Exhibit No.
|
Description
|
|
|
99.1
|
Press
Release dated May 11, 2009.
|
Exhibit
99.1
FOR
IMMEDIATE RELEASE
|
Company
Contact:
|
Investor
Relations Contacts:
|
Media
Contact:
|
|
AngioDynamics,
Inc.
|
EVC Group,
Inc.
|
EVC Group,
Inc.
|
|
D.
Joseph Gersuk, CFO
|
Doug
Sherk/Jenifer Kirtland
|
Chris
Gale/ Steve DiMattia
|
|
(800)
772-6446 x1608
|
(415)
896-2005
|
(646)
201-5431
|
|
jgersuk@AngioDynamics.com
|
dsherk@evcgroup.com
|
cgale@evcgroup.com
|
|
jkirtland@evcgroup.com
|
sdimattia@evcgroup.com
|
Jan
Keltjens Appointed to Board of Directors of AngioDynamics
QUEENSBURY, N.Y. May 11, 2009 — AngioDynamics, Inc.
(NASDAQ: ANGO), a leading provider of innovative medical devices used by
interventional radiologists and surgeons for the minimally-invasive treatment of
cancer and peripheral vascular disease, today announced Jan Keltjens, 52,
President and Chief Executive Officer of the Company, has been appointed to its
Board of Directors. Mr. Keltjens replaces Eamonn Hobbs, who has resigned from the Board of Directors.
“On
behalf of the Board of Directors, I would like to thank Eamonn for all his
contributions to AngioDynamics, both as the company’s co-founder and
previous chief executive officer, as well as most recently as a member of the
Board. We all wish him the very best in his future endeavors,” said Vincent
Bucci, Chairman of the Board of Directors. “At the same time, the Board looks
forward to working with Jan in his expanded role with
AngioDynamics. During his short tenure as our president and chief
executive officer, his performance has reinforced the Board’s confidence in his
leadership of the Company.”
Mr.
Keltjens joined AngioDynamics as President and CEO on March 1,
2009. Most recently, he was President and CEO of CryoCath
Technologies, Inc. Mr. Keltjens also previously served in various
leadership positions at Cordis, a Johnson & Johnson company, including his
last position as Worldwide General Manager of Cordis Neurovascular.
About
AngioDynamics
AngioDynamics,
Inc. is a leading provider of innovative medical devices used by interventional
radiologists, surgeons and other physicians for the minimally-invasive treatment
of cancer and peripheral vascular disease. The Company’s diverse product
line includes market-leading radiofrequency and irreversible electroporation
ablation systems, vascular access products, angiographic products and
accessories, dialysis products, angioplasty products, drainage products,
thrombolytic products, embolization products and venous products. More
information is available at www.angiodynamics.com.
# # #